253 related articles for article (PubMed ID: 25144771)
1. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.
Farrow AL; Rachakonda G; Gu L; Krendelchtchikova V; Nde PN; Pratap S; Lima MF; Villalta F; Matthews QL
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3089. PubMed ID: 25144771
[TBL] [Abstract][Full Text] [Related]
2. Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease.
Matthews QL; Farrow AL; Rachakonda G; Gu L; Nde P; Krendelchtchikov A; Pratap S; Sakhare SS; Sabbaj S; Lima MF; Villalta F
Pathog Immun; 2016; 1(2):214-233. PubMed ID: 27709126
[TBL] [Abstract][Full Text] [Related]
3. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.
Farrow AL; Peng BJ; Gu L; Krendelchtchikov A; Matthews QL
Viruses; 2016 Mar; 8(3):78. PubMed ID: 26978385
[TBL] [Abstract][Full Text] [Related]
4. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.
Miyahira Y; Takashima Y; Kobayashi S; Matsumoto Y; Takeuchi T; Ohyanagi-Hara M; Yoshida A; Ohwada A; Akiba H; Yagita H; Okumura K; Ogawa H
Infect Immun; 2005 Nov; 73(11):7356-65. PubMed ID: 16239534
[TBL] [Abstract][Full Text] [Related]
5. Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.
Gu L; Farrow AL; Krendelchtchikov A; Matthews QL
J Vis Exp; 2015 May; (99):e52655. PubMed ID: 25993057
[TBL] [Abstract][Full Text] [Related]
6. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
[TBL] [Abstract][Full Text] [Related]
7. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
Front Immunol; 2020; 11():1279. PubMed ID: 32695105
[TBL] [Abstract][Full Text] [Related]
8. Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.
Nogueira RT; Nogueira AR; Pereira MC; Rodrigues MM; Galler R; Bonaldo MC
Virol J; 2011 Mar; 8():127. PubMed ID: 21418577
[TBL] [Abstract][Full Text] [Related]
9. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.
Garg N; Tarleton RL
Infect Immun; 2002 Oct; 70(10):5547-55. PubMed ID: 12228281
[TBL] [Abstract][Full Text] [Related]
10. Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.
Barbosa RP; Filho BG; Dos Santos LI; Junior PA; Marques PE; Pereira RV; Cara DC; Bruña-Romero O; Rodrigues MM; Gazzinelli RT; Machado AV
PLoS One; 2013; 8(4):e61795. PubMed ID: 23637908
[TBL] [Abstract][Full Text] [Related]
11. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
12. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.
Gu L; Krendelchtchikova V; Krendelchtchikov A; Farrow AL; Derdeyn CA; Matthews QL
Virology; 2016 Jan; 487():75-84. PubMed ID: 26499044
[TBL] [Abstract][Full Text] [Related]
14. A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.
Gu L; Krendelchtchikova V; Krendelchtchikov A; Oster RA; Fujihashi K; Matthews QL
Virol J; 2014 Jun; 11():112. PubMed ID: 24935650
[TBL] [Abstract][Full Text] [Related]
15. Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi.
Wrightsman RA; Manning JE
Vaccine; 2000 Jan; 18(14):1419-27. PubMed ID: 10618540
[TBL] [Abstract][Full Text] [Related]
16. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.
Serna C; Lara JA; Rodrigues SP; Marques AF; Almeida IC; Maldonado RA
Vaccine; 2014 Jun; 32(28):3525-32. PubMed ID: 24793944
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.
Wizel B; Garg N; Tarleton RL
Infect Immun; 1998 Nov; 66(11):5073-81. PubMed ID: 9784506
[TBL] [Abstract][Full Text] [Related]
18. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
Fralish BH; Tarleton RL
Vaccine; 2003 Jun; 21(21-22):3070-80. PubMed ID: 12798651
[TBL] [Abstract][Full Text] [Related]
19. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
20. A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.
Fonseca JA; Cabrera-Mora M; Kashentseva EA; Villegas JP; Fernandez A; Van Pelt A; Dmitriev IP; Curiel DT; Moreno A
PLoS One; 2016; 11(4):e0154819. PubMed ID: 27128437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
